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dupilumab, a fully human mAb targeting IL-4 receptor a,
markedly improved disease activity, but the effect of IL-4/IL-13
blockade onADat themolecular level has not been characterized.
Objectives: We sought to evaluate dupilumab modulation of the
AD molecular signature.
Methods: We performed transcriptomic analyses of
pretreatment and posttreatment skin biopsy specimens from
patients with moderate-to-severe AD treated weekly with 150 or
300 mg of dupilumab or placebo.
Results: Exacerbation of the AD transcriptome was observed in
placebo-treated patients. Dupilumab improved the AD
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dupilumab by 26% (95% CI, 21% to 32%) and 65% (95% CI,
60% to 71%) for treatment with 150 and 300 mg, respectively.From aRegeneron Pharmaceuticals, Tarrytown; bthe Laboratory for Investigative Derma-
tology, Rockefeller University, New York; cSanofi, Bridgewater; and dthe Department
of Dermatology, Icahn School of Medicine at Mount Sinai, New York.
*These authors contributed equally to this work.
Supported by Regeneron Pharmaceuticals and Sanofi (NCT01259323, NCT01385657).
Disclosure of potential conflict of interest: J. D. Hamilton and A. R. Radin are employed
by Regeneron, have patents through Regeneron, and receive stock/stock options as part
of their compensation. M. Suarez-Fari~nas has received research support from and has
consultant arrangements with Regeneron. I. Cardinale and X. Li have received
research support from Regeneron. A. Kostic and N. Graham are employed by Regen-
eron and receive stock/stock options as part of their compensation. J. E. Ming and G.
Pirozzi are employed by Sanofi and receive stock/stock options as part of their
compensation. J. G. Krueger has received grants paid to the institution and personal
fees from Novartis, Pfizer, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer,
BMS, and Paraxel during the conduct of the study; grants paid to the institution
from Amgen, Innovaderm and Kyowa; and personal fees from Serono, Biogen Idec,
Delenex, AbbVie, Sanofi, Baxter, Xenoport, and Kineta.G. D. Yancopoulos is a board
member for Regeneron, is employed as Chief Science Officer for Regeneron, and re-
ceives stock/stock options as part of his compensation. E. Guttman-Yassky has
received research support from Regeneron, BMS, Janssen, Celgene, and Leo Pharma;
has board memberships with Regeneron, Sanofi, Celgene, GlaxoSmithKline/Stiefel,
MedImmune, and Leo Pharma; and has consultant arrangements with Regeneron, Cel-
gene, BMS, Dermima, MedImmune, GlaxoSmithKline/Stiefel, and Galderma. The
rest of the authors declare that they have no relevant conflicts of interest.
Received for publication August 29, 2014; revised October 13, 2014; accepted for pub-
lication October 14, 2014.
Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology
and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at
Mount Sinai Medical Center, 5 East 98th St, New York, NY 10029. E-mail: Emma.
Guttman@mountsinai.org.
0091-6749
 2014 The Authors. Published by Elsevier Inc. on behalf of the American Academy
of Allergy, Asthma & Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.jaci.2014.10.013Genes downregulated in AD lesions increased by 21% (95% CI,
16% to 27%) and 32% (95% CI, 26% to 37%) with dupilumab
(150 and 300 mg, respectively). The molecular changes
paralleled improvements in clinical scores. A dupilumab
treatment signature of 821 probes (>2-fold change, P < .05)
significantly modulated in the 300-mg dupilumab group at week
4 compared with baseline was identified in this sample set.
Significant (P < .05) decreases in mRNA expression of genes
related to hyperplasia (K16 and MKI67), T cells, and dendritic
cells (CD1b and CD1c) and potent inhibition of TH2-associated
chemokines (CCL17, CCL18, CCL22, and CCL26) were noted
without significant modulation of TH1-associated genes (IFNG).
Conclusions: This is the first report showing rapid improvement
of the AD molecular signature with targeted anti–IL-4 receptor
a therapy. These data suggest that IL-4 and IL-13 drive a
complex, TH2-centered inflammatory axis in patients with AD.
(J Allergy Clin Immunol 2014;134:1293-300.)
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Atopic dermatitis (AD), the most common inflammatory skin
disorder, has a prevalence of 10% in adults (in the United States)
and up to 25% among children (worldwide); approximately 20%
of patients have moderate-to-severe disease.1 Although AD
imposes a substantial burden on patients and the health care
system,2-5 the physical and psychological effects are often under-
estimated. These effects might be reflected by a marked increase
in suicidal ideation in patients with AD.6-8
Despite the increasing worldwide incidence of AD, treatments
are limited,with only 3 approved (depending on country) systemic
therapeutic options for patients with severe disease who are
inadequate responders to topical agents: oral corticosteroids, oral
cyclosporin A (CsA), and UVA1/narrow-band UVB (NB-UVB)
phototherapy.9 These therapies are not uniformly effective, and
their use is limited by toxicity (corticosteroids and CsA) or incon-
venience (NB-UVB). Thus there is an unmet need for a safe and
effective systemic treatment for this subset of patients.
It is thought that AD is fundamentally a disease of barrier
dysfunction. However, active AD lesions are always accompa-
nied by underlying immune activation.10,11 Skin lesions have
been best characterized in chronic AD skin and defined as lesions
persisting for more than 3 days. Features usually present in
chronic lesions include increased infiltration by T cells, dendritic
cells (DCs), and eosinophils; increased production of cytokines
and chemokines; and reactive epidermal hyperplasia, in which1293
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highly suppressed.12-14 Although AD has been classified as a
TH2-dominated disease, other T-cell subsets (TH22, TH17, and
TH1 cells) might also contribute to pathogenesis.
9-11,15
On the basis of the hypothesis that IL-4 and IL-13 are key
drivers of clinical disease and that IL-4 receptor a (IL-4Ra) is a
requisite receptor for signaling from both cytokines, we tested
whether blocking IL-4Ra could modify molecular mechanisms
of AD pathogenesis in the skin. Dupilumab, a fully humanmAb to
IL-4Ra that inhibits both IL-4 and IL-13 signaling, is being tested
as a potential therapy for AD, asthma, and nasal polyps. We
recently reported positive results in early-phase trials in both
patients with AD16 and a TH2-enriched subpopulation of asth-
matic patients.17 In this report we relate the efficacy observed in
phase 1 studies to molecular changes in the skin.18 This is the first
study to evaluate the relationship between themolecular effects of
a targeted TH2 antagonist and AD pathomechanisms.
METHODS
Study subjects and skin samples
Pretreatment and posttreatment lesional skin biopsy specimens (LSs) and
nonlesional skin biopsy specimens (NLs; >_1 cm from any active lesion) were
obtained from 18 adult patients with moderate-to-severe chronic AD (Table I)
who participated in 2 phase 1 studies and provided additional consent for the
biopsy specimens. Both studies were multicenter, randomized, double-blind,
placebo-controlled trials of weekly subcutaneous injections of 150 or 300
mg of dupilumab or placebo for 4 weeks (baseline and weeks 1-3) under insti-
tutional review board–approved protocols (NCT01259323 and
NCT01385657).16 Biopsy specimens were collected 1 week after the last
dose (protocol-defined end of treatment and primary end point).
Patients were allowed to use emollients, with no additional therapy during
treatment. Baseline and week 4 LSs and NLs were obtained from the patients
treated with placebo and dupilumab (150 or 300 mg). Disease severity was
evaluated by using the Eczema Area and Severity Index (EASI) score19 at
baseline and week 4 (Table I).
RNA analyses
Expression profiling was performed to evaluate the effects of IL-4Ra
blockade on LSs and NLs from patients with AD. RNA was extracted,
followed by quantitative RT-PCR (qRT-PCR) and Affymetrix Human
U133Plus 2.0 arrays (Affymetrix, Santa Clara, Calif) analyses, as previously
described.18 qRT-PCR was used to assess the expression of key AD-related
genes and microarray findings (primers and probes are listed in Table E1 in
this article’s Online Repository at www.jacionline.org).
Statistical analysis
Quality control ofmicroarray chips was carried out with standardQCmetrics
and R package microarray Quality Control. Images were scrutinized for spatial
artifacts by usingHarshlight.20 Expressionmeasures were obtained by using theGCRMA algorithm.21 A batch effect was observed in the original data, corre-
sponding to the date of hybridization, and linear models in the R limma frame-
work were used to adjust the expression values to eliminate this effect.
Additionally, the batch-specific coefficients of the linear model were estimated
sequentially because the variable ‘‘tissue’’ was unbalanced in the third batch,
which contained only NLs. The first 2 batches, containing both LSs and NLs,
were used to estimate batch 1 and batch 2 coefficients, whereas only nonlesional
pretreatment samples were used to estimate the batch 3 coefficient.
Probe sets with at least 3 samples, expression values of greater than 3, and
SDs of greater than 0.1 were kept for further analysis. Expression values were
modeled by usingmixed-effectmodels, with time and treatment as fixed factors,
and a random effect for each patient. This approach intrinsically models within-
patient correlation similar to a paired t test and estimates the main effects even
with missing values. Fold changes for the comparisons of interest were esti-
mated, and hypothesis testing was conducted with contrasts under the general
framework for linear models in the R limma package. P values from the moder-
ated (paired) t tests were adjusted for multiple hypotheses by using the
Benjamini-Hochberg procedure. Hierarchic clustering was performed with
Euclidean distance and a Mcquitty agglomeration scheme.20,21
To evaluate the treatment effect on the published AD transcriptome
(differentially expressed genes between lesional and nonlesional skin), we
used a previously applied strategy.22 The improvement in the AD transcrip-
tome of lesional skin was defined as treatment-associated changes in gene
expression toward a nonlesional molecular phenotype. A ‘‘worsening’’ or
exacerbation was defined as gene expression changes further distinguishing
LSs from NLs. The qRT-PCR analysis used log-transformed expression
values, as previously reported.22 Pearson rank correlations were used to eval-
uate the association of all variables measured by using qRT-PCR with treat-
ment responses. For more information, see the Methods section in this
article’s Online Repository at www.jacionline.org.RESULTS
As recently reported, EASI scores improved significantly in
adults treated with dupilumab compared with scores in those
receiving placebo.16 The mean percentage change in EASI scores
in the biopsy substudy (n 5 18) was consistent with that of the
parent studies (n 5 67; Fig 1, A, and Table I). The pretreatment
serum IgE level was greater than 150 kU/L in 14 of 18 substudy
patients, and the majority of patients had positive Phadiatop test
results, indicating sensitization to at least 1 allergen (Table I).
EASI-50 data for each treatment arm are also listed in Table I
and show that EASI-50, which represents at least 50% improve-
ment in EASI score relative to baseline, was achieved by all but
1 patient in the substudy treated with 300 mg of dupilumab versus
none in the placebo group.Improvement of the AD transcriptome
After 4weeks of treatment, significant dose-dependent changes
from baseline in the previously defined AD transcriptome
(differentially expressed genes between lesional and nonlesional
AD skin) were detected in LSs by using microarrays in the
dupilumab group compared with the placebo arm of the study.22
Dose-dependent changes of 226% (SEM, 2.17%) and 265%
(SEM, 3.45%) in upregulated genes were observed in the patients
treated with 150 and 300 mg of dupilumab, respectively, with
accompanying changes of 132% (SEM, 2.44%) and 121%
(SEM, 1.69%) in downregulated genes (Fig 1, B, and see Fig
E1 and Table E2 in this article’s Online Repository at www.
jacionline.org). In placebo-treated patients a worsening of the
AD signature was observed by 112% (SEM, 2.46%; 95% CI,
7% to 17%) in upregulated and by 231% (SEM, 3.66%; 95%
CI, 25% to 36%) in downregulated genes. These molecular
TABLE I. Baseline and treatment response in biopsy substudy participants and the parent trials
Characteristic
Biopsy substudy Combined parent trials
Placebo
(n 5 4)
Dupilumab,
150 mg (n 5 7)
Dupilumab,
300 mg (n 5 7)
Placebo
(n 5 16)
Dupilumab,
150 mg (n 5 22)
Dupilumab,
300 mg (n 5 21)
Age (y), mean (SD) 40.8 (26.1) 38.0 (10.4) 60.6 (15.9) 37.4 (17.2) 42.5 (11.4) 45.4 (15.9)
Male sex, no. (%) 3 (75) 5 (71) 6 (86) 11 (69) 12 (55) 10 (48)
Baseline EASI score, mean (SD) 23.6 (7.7) 30.5 (16.3) 28.2 (8.1) 22.8 (12.0) 30.0 (17.0) 27.4 (11.2)
Percentage change in EASI score,
week 4, mean (SD)
223.6 (8.1) 243.8 (41.1) 268.9 (22.5) 225.4 (35.0) 255.0 (30.4) 264.3 (25.8)
EASI-50 responders at week 4 (%) 0* 42.9 85.7 18.8 54.5 71.4
Baseline serum total IgE (kU/L),
geometric mean (95% CI)
2,833
(269.9-29,736.1)
1,090.3
(226.3-5,252.8)
193.2
(34.2-1,090.7)
2,227.8
(605.8-8,188.0)
1,965.0
(885.9-4,358.3)
521.1
(186.3-1,457.7)
Percentage change in IgE level at
week 4, mean (SD)
13.5* 27 (24) 213 (13) 10 (30) 22 (26) 24 (22)
Phadiatop result positive at
baseline, no. (%)
4 (100) 6 (86) 5 (71) 14 (88) 20 (91) 17 (81)
*Week 4 data were only available for 2 of 4 patients in the placebo group.
Baseline Phadiatop data were only available from 6 of 7 patients.
FIG 1. Clinical and molecular changes with dupilumab. A, Clinical responses (percentage change in
EASI score) in the substudy were similar to parent trials. Bar plots represent means 6 SEMs. B,
Dose-dependent changes in the AD transcriptome with dupilumab (150/300 mg) versus placebo. Bar plots
represent means 6 SEMs. C, Transcriptomic differences between lesional and nonlesional skin showed
dose-dependent decreases with dupilumab. Red indicates upregulated and blue indicates downregulated
genes in theAD transcriptome (lesional vs nonlesional).Week4NLswere not available for theplacebogroup.
Bar plots represent means6 SDs. P values of changes from baseline or between groups are listed.
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FIG 2. Pretreatment versus posttreatment gene expression profiles. A,Differentially expressed genes (DEG)
with all treatments. B, Heat map of an immune gene subset. Upregulation of inflammatory genes character-
izes lesional skin at baseline. Whereas inflammatory genes were strongly downregulated with 300 mg of
dupilumab (red to blue transition in pretreatment vs posttreatment lesional samples), no changes were
seen with placebo. Red indicates gene upregulation and blue indicates gene downregulation with
treatment.
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EASI scores (Fig 1, A, and Table I). For example, there was a
74% difference between the 300-mg dupilumab group compared
with the placebo arm (152% improvement in the 300-mg group
vs an overall exacerbation of 221.5% in the placebo group). In
contrast, only a 45.3% difference between the 300-mg dupilumab
and placebo arms was observed for the percentage change in
EASI scores (Fig 1, A and B). The molecular differences between
lesional and nonlesional skin before treatment were minimized in
a dose-dependent manner, which was most evident in the 300-mg
dupilumab group (Fig 1, C).Differential gene expression with treatment at
week 4
Additional differences in gene expression not limited to the
previously defined AD transcriptome between week 4 and baseline
were determined in LSs of patients treated with dupilumab and
placebo (Fig 2, A, and see Table E3 in this article’s Online Repos-
itory at www.jacionline.org). As shown in the heat map in Fig 2, A,
dose-dependent changes with treatment were most evident in the
300-mg dupilumab group. Strikingly, the LS transcriptome after
treatment with 300 mg of dupilumab resembles that of nonlesionalskin (Fig 2, A). At week 4, 821 probes (473 upregulated and 348
downregulated) were significantlymodulatedwith 300mg of dupi-
lumab versus only 275 probes with placebo (105 and 160 upregu-
lated and downregulated, respectively; >2-fold change, P < .05;
see Table E3).Markers of epidermal proliferation (MKI67), keratin
16 (K16), keratin 6B (K6B), and multiple inflammatory mediators
were among the large set of genes downregulated by dupilumab
(Fig 2, A, and see Table E3). Among the top genes upregulated
with dupilumab were those with structural (eg, MATN4), lipid
metabolism (eg, PLIN4, ADIPOQ, and PLIN1), and barrier-
related (eg, CLDN8, ELN, and CLDN11) functions (see Table
E3). Expression of some of these genes decreased in the placebo
group (eg, PLIN4, CLDN11, and ADIPOQ). Among the most
significantly downregulated immune genes were inflammatory
markers (MMP12 and S100A12), T-cell markers (eg, ITK and
ICOS), TH2 and eosinophil-attracting chemokines (eg, CCL13
and CCL26), DC antigens (ITGAX/CD11c, CD1b, and CD83),
and keratinocyte-associated mediators (IL6, IL8, and IL7R; Figs 2
and 3 and see Tables E3 and E4 in this article’s Online Repository
at www.jacionline.org). By using Gene Set Enrichment Analysis to
evaluate changes in an immunegene-subset, a prominentmolecular
signal of inflammation was seen in lesional skin at baseline (Fig 2,
B, and see Table E4). Dose-dependent decreases were observed
FIG 3. A summary heat map of all quantitative RT-PCR mRNA expression
changes with treatments. Dose-dependent inhibition of epidermal prolif-
eration and inflammatory markers were observed in biopsy specimens
from patients treated with 150 or 300 mg of dupilumab for 4 weeks
compared with exacerbations with placebo. Values represent the mean
fold change (FCH) 6 SEM. *P < .1, **P < .05, and ***P < .01.
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mune phenotypewith 300mgof dupilumab.No significant changes
in this immune subset were seen with placebo (Fig 2, B).Dose-dependent mRNA suppressions of immune
and epidermal responses measured by using
qRT-PCR
To measure modulation of various immune axes activated in
lesional skin, we performed qRT-PCR for a wide array of mRNAs
shown in Figs 3 and 4 (red indicates upregulation and blue indi-
cates downregulation). With 300 mg of dupilumab, there was
strong and significant modulation of TH2-associated chemokines
(CCL13, CCL17, CCL18, and CCL26) and some epidermal prod-
ucts, particularly the proliferation marker K16 and elafin (PI3),whereas increased immune activation was observed with placebo
(Figs 3 and 4 and see Fig E2 in this article’s Online Repository at
www.jacionline.org). No significant changes with treatment were
observed in mRNAs of major TH2 cytokines (IL4, IL13, IL5, and
IL31; see Fig E3 in this article’s Online Repository at www.
jacionline.org).
Although one might hypothesize that inhibiting the TH2
pathway would upregulate TH1 activity, increases in TH1/IFN-
g–related gene expression were not observed with dupilumab
treatment. In fact, small decreases in expression of these genes
(IFNG, OASL,MX1, and CXCL10) were detected by using arrays
and qRT-PCR for the treatment arms, whereas expression of some
of these genes increased with placebo (Figs 3 and 4 and see Tables
E2 and E3).
IL17A and IL22mRNAswere not significantly reduced at week
4 with dupilumab. However, significant suppression of IL-17/IL-
22–modulated genes (ie, CXCL1, CXCL2, PI3, IL-23p19/IL-23A,
and S100 genes) was observed with dupilumab treatment
compared with placebo. CCL20 expression significantly
increased with placebo. Of the IL-17/IL-22–modulated genes,
PI3 and S100A12 showed the greatest suppression with 300 mg
of dupilumab (Figs 3 and 4 and see Fig E3).
The barrier defect in patients with AD is characterized by
hyperplasia (asmeasured by the proliferationmarkerK16), induc-
tion of S100As, and suppression of terminal differentiation (ie,
FLG and LOR).9,11 Four weeks of 300 mg of dupilumab resulted
in significant suppression of K16 (210.7-fold change, P < .001,
Fig 3). We also observed significant decreases in expression of
S100A genes (ie, S100A12 and S100A8) and a modest trend of in-
creases in terminal differentiation proteins (Figs 3 and 4). Dose-
dependent increases in terminal differentiation genes were
observed with dupilumab after adjusting for changes in hyperpla-
sia (as measured by K16 mRNA changes, see Fig E4 in this arti-
cle’s Online Repository at www.jacionline.org).
When assessing dupilumab’s effects on gene signatures for
epidermal differentiation, cytokine-treated keratinocytes, and
various immune axes,22-24 dose-dependent responses from base-
line were observed, with concurrent exacerbations with placebo
(Fig 5 and see Table E5 in this article’s Online Repository at
www.jacionline.org). Substantial suppression of the TH17 signa-
ture was observed in the 300-mg dupilumab group (with a large
exacerbation in the placebo group).Correlation with improvements in disease activity
We evaluated the association of the markers measured by using
qRT-PCR with clinical improvement by determining the Pearson
correlations of the change with treatment of each variable
measured in lesional skin with EASI score improvements (data
not shown). Reductions in CCL26 and CCL13 expression had the
highest correlation with improvement in percentage change in the
EASI score (CCL26: r5 0.8, P5 .005;CCL13: r5 0.55, P5 .1).
In patients who achieved 50% or greater improvement in EASI
scores,K16 showed the highest correlation with clinical improve-
ment (r 5 0.98, P 5 .01; data not shown).DISCUSSION
This is the first evaluation of a targeted immune antagonist in
patients with AD that correlates mechanistic changes with
clinical measures of disease. Previous studies with broad
FIG 4. Dupilumab (DPL)– and placebo-induced lesional skin changes in inflammatory and epidermal
markers, as quantified by using qRT-PCR. Panels A through S show posttreatment versus pretreatment
mRNA expression differences (fold change) of selected genes, as grouped by inflammatory pathway, in le-
sional skin at week 4 of treatment. Values represent means6 SEMs with posttreatment versus pretreatment
P values compared with baseline. FCH, Fold change.
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demonstrated clinical improvements (using EASI or SCORAD
scores),25-27 but most lacked evaluations of molecular markers.
We recently established a relationship between activation of
cytokine pathways and epidermal alterations in skin and clinical
disease activity in a CsA study.24 However, studies with targeted
immune antagonists are needed to understand the contributionof specific cytokine pathways to the epidermal pathology in pa-
tients with AD.
In this study statistically significant, dose-dependent improve-
ments of the AD transcriptome were observed in patients treated
with 4 weeks of dupilumab compared with placebo.
Dupilumab suppressed mRNA expressions of genes related to
activation of T cells, DCs, eosinophils, inflammatory pathways,
FIG 5. Dose-dependent genomic changes were observed by using microarrays in previously defined
immune pathways and epidermal gene subsets with dupilumab. Transcriptomic improvement refers to
transition toward a noninflammatory molecular phenotype. Values represent means 6 95% CIs. Numbers
in the bottom row represent the number of probes representing AD genes in each pathway. Detailed gene
lists are provided in Table E5.
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insignificant decreases observed with placebo. Although we did
not detect significant reductions in IL-17A or IL-22 levels, large
reductions in expression of IL-17–related genes, such as elafin
(PI3), IL23p19/IL23A, and S100A8 and trends for suppression
(CXCL1 and S100A7) were found with 300 mg of dupilumab.
Furthermore, with placebo, there was an overall exacerbation of
the inflammatory AD lesional phenotype, with large increases
in expression of TH17-associated genes, particularly CCL20.
These results are consistent with recent findings from flaky tail
mice suggesting IL-4 signaling might be regulated, at least in
part, by the IL-17 pathway (IL-17A deficiency attenuated TH2
inflammation in this model).28
The treatment was associated with a dose-response reversal
of the epidermal lesional phenotype. In particular, major
suppressions of hyperplasia-related genes (eg, K16) and reduc-
tions in expression of S100A genes were evident with 300 mg of
dupilumab by using microarrays and qRT-PCR. The reduction
in K16 expression was of greater magnitude than that observed
in patients with similar disease severity treated for 12 weeks
with 5 mg/kg CsA.24 We also measured changes in other critical
epidermal alterations in AD skin, including significant increases
in claudin and lipid product levels with 300 mg of dupilumab,
whereas decreases were observed in the placebo group. A trend
of dose-dependent increases in expression of differentiation
genes (LOR and FLG) was observed after adjusting for suppres-
sion of epidermal hyperplasia, as demonstrated by K16 reduc-
tions with dupilumab. Increases in LOR and FLG expression
were also seen with placebo, but these can be attributed to
the increased epidermal hyperplasia in the placebo arm and
were not evident after adjusting for K16 expression. These
data suggest that IL-4/IL-13 blockade might restore abnormallipid and differentiation alterations in the skin of patients
with AD.29
No significant differences were found in either clinical or tissue
(molecular) responses to treatment between patients with normal
or increased serum total IgE levels.16 These results suggest the hy-
pothesized model of barrier inhibition through activation of TH2
cytokines could be operative in most patients with AD, regardless
of IgE levels, and that targeting TH2 inflammation might be
an efficacious treatment for patients with either intrinsic or
extrinsic AD.18,30
These data are consistentwith the suggested roles of IL-4 and IL-
13 in patients with AD and the proposal that dual antagonism of
these cytokines with a single agent has the potential to potently
inhibit TH2 effector responses. The IL-4 and IL-13 cytokines have
been suggested to exert several effects in AD, including activation
and survival of TH2 T cells, induction of differentiation and activa-
tion ofmyeloid and atopicDCs, activation of B cells, stimulation of
IgE class-switching, and eosinophil recruitment.31-34 IL-4 and IL-
13 also suppress lipid production and keratinocyte differentiation,
ultimately disrupting the epidermal barrier, with possible feedback
pathways that could induce epidermal hyperplasia.32,35-37
These data support AD as an immune-driven disease and
establish IL-4 and IL-13 as pathogenic cytokines in patients with
AD, driving complex TH2-centered inflammation that regulates
epidermal responses. The data also provide further evidence
that IL-4 is a key regulator of TH17 activity in AD skin. Because
IL-4Ra is expressed on many inflammatory cells involved in
AD (eg, keratinocytes, T cells, DCs, and eosinophils),13,37 block-
ing signaling through this receptor might exert a range of
anti-inflammatory effects beyond the known TH2 axis. Modu-
lating IL-4/IL-13 signaling through IL-4Ra inhibition might be
an effective method for treating existing skin lesions and for
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tion of a single target has the potential to reverse AD pathome-
chanisms, opening the door to a new era of targeted treatment
for this common and debilitating inflammatory skin disease.
Dupilumab trials to evaluate longer-term disease suppression,
including cellular andmolecular analyses of changes in epidermal
pathology and immune abnormalities, are underway. These larger
studies of longer treatment duration will not only clarify the effect
of dupilumab on lesional skin but might also provide greater
insight as to whether nonlesional skin is normalized.22 These
studies might also be used to compare the long-term dupilumab
data with studies using conventional treatments (ie, CsA and
NB-UVB),18,24 as well as the respective molecular remnants
across conventional and specific therapeutic agents.38,39 Molecu-
lar effects of dupilumab on the AD transcriptome in larger studies
should also consider recognized AD subtypes based on IgE level,
ethnicity, and other variables.40
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Clinical implications: Targeted therapeutics might open the
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